Literature DB >> 33519816

CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.

Cedric Bosteels1,2, Kaat Fierens1,2, Sofie De Prijck1,2, Justine Van Moorleghem1,2, Manon Vanheerswynghels1,2, Caroline De Wolf1,2, Aurélie Chalon3, Catherine Collignon3, Hamida Hammad1,2,4, Arnaud M Didierlaurent3, Bart N Lambrecht1,2,4.   

Abstract

The Adjuvant System AS01 contains monophosphoryl lipid A (MPL) and the saponin QS-21 in a liposomal formulation. AS01 is included in recently developed vaccines against malaria and varicella zoster virus. Like for many other adjuvants, induction of adaptive immunity by AS01 is highly dependent on the ability to recruit and activate dendritic cells (DCs) that migrate to the draining lymph node for T and B cell stimulation. The objective of this study was to more precisely address the contribution of the different conventional (cDC) and monocyte-derived DC (MC) subsets in the orchestration of the adaptive immune response after immunization with AS01 adjuvanted vaccine. The combination of MPL and QS-21 in AS01 induced strong recruitment of CD26+XCR1+ cDC1s, CD26+CD172+ cDC2s and a recently defined CCR2-dependent CD64-expressing inflammatory cDC2 (inf-cDC2) subset to the draining lymph node compared to antigen alone, while CD26-CD64+CD88+ MCs were barely detectable. At 24 h post-vaccination, cDC2s and inf-cDC2s were superior amongst the different subsets in priming antigen-specific CD4+ T cells, while simultaneously presenting antigen to CD8+ T cells. Diphtheria toxin (DT) mediated depletion of all DCs prior to vaccination completely abolished adaptive immune responses, while depletion 24 h after vaccination mainly affected CD8+ T cell responses. Vaccinated mice lacking Flt3 or the chemokine receptor CCR2 showed a marked deficit in inf-cDC2 recruitment and failed to raise proper antibody and T cell responses. Thus, the adjuvant activity of AS01 is associated with the potent activation of subsets of cDC2s, including the newly described inf-cDC2s.
Copyright © 2021 Bosteels, Fierens, De Prijck, Van Moorleghem, Vanheerswynghels, De Wolf, Chalon, Collignon, Hammad, Didierlaurent and Lambrecht.

Entities:  

Keywords:  AS01; CD64; Fc receptor; MAR-1; adjuvant; dendritic cell; inf-cDC2; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33519816      PMCID: PMC7841299          DOI: 10.3389/fimmu.2020.606805

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  60 in total

1.  CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis.

Authors:  Samira Tamoutounour; Sandrine Henri; Hugues Lelouard; Béatrice de Bovis; Colin de Haar; C Janneke van der Woude; Andrea M Woltman; Yasmin Reyal; Dominique Bonnet; Dorine Sichien; Calum C Bain; Allan McI Mowat; Caetano Reis e Sousa; Lionel F Poulin; Bernard Malissen; Martin Guilliams
Journal:  Eur J Immunol       Date:  2012-10-17       Impact factor: 5.532

2.  Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.

Authors:  Najoua Dendouga; Michel Fochesato; Laurence Lockman; Sally Mossman; Sandra L Giannini
Journal:  Vaccine       Date:  2012-02-10       Impact factor: 3.641

3.  Complement receptor C5aR1/CD88 and dipeptidyl peptidase-4/CD26 define distinct hematopoietic lineages of dendritic cells.

Authors:  Hideki Nakano; Timothy P Moran; Keiko Nakano; Kevin E Gerrish; Carl D Bortner; Donald N Cook
Journal:  J Immunol       Date:  2015-03-13       Impact factor: 5.422

4.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.

Authors: 
Journal:  Lancet       Date:  2015-04-23       Impact factor: 79.321

Review 5.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

6.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

7.  Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01.

Authors:  Sophie Detienne; Iain Welsby; Catherine Collignon; Sandrine Wouters; Margherita Coccia; Sophie Delhaye; Laurye Van Maele; Séverine Thomas; Maëlle Swertvaegher; Aurélie Detavernier; Abdelatif Elouahabi; Stanislas Goriely; Arnaud M Didierlaurent
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

8.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Authors:  Margherita Coccia; Catherine Collignon; Caroline Hervé; Aurélie Chalon; Iain Welsby; Sophie Detienne; Mary J van Helden; Sheetij Dutta; Christopher J Genito; Norman C Waters; Katrijn Van Deun; Age K Smilde; Robert A van den Berg; David Franco; Patricia Bourguignon; Sandra Morel; Nathalie Garçon; Bart N Lambrecht; Stanislas Goriely; Robbert van der Most; Arnaud M Didierlaurent
Journal:  NPJ Vaccines       Date:  2017-09-08       Impact factor: 7.344

9.  The lung vascular filter as a site of immune induction for T cell responses to large embolic antigen.

Authors:  Monique A M Willart; Hendrik Jan de Heer; Hamida Hammad; Thomas Soullié; Kim Deswarte; Björn E Clausen; Louis Boon; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more
  10 in total

Review 1.  Fungal-mediated lung allergic airway disease: The critical role of macrophages and dendritic cells.

Authors:  Julio Furlong-Silva; Peter Charles Cook
Journal:  PLoS Pathog       Date:  2022-07-14       Impact factor: 7.464

2.  Monocytes Elicit a Neutrophil-Independent Th1/Th17 Response Upon Immunization With a Mincle-Dependent Glycolipid Adjuvant.

Authors:  Christiane Desel; Peter J Murray; Christian H K Lehmann; Lukas Heger; Dennis Christensen; Peter Andersen; Matthias Mack; Diana Dudziak; Roland Lang
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

3.  Recruitment of dendritic cell progenitors to foci of influenza A virus infection sustains immunity.

Authors:  Mar Cabeza-Cabrerizo; Carlos M Minutti; Mariana Pereira da Costa; Ana Cardoso; Robert P Jenkins; Justina Kulikauskaite; Michael D Buck; Cécile Piot; Neil Rogers; Stefania Crotta; Lynne Whittaker; Hector Huerga Encabo; John W McCauley; Judith E Allen; Manolis Pasparakis; Andreas Wack; Erik Sahai; Caetano Reis e Sousa
Journal:  Sci Immunol       Date:  2021-11-05

Review 4.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

5.  Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells.

Authors:  Monika Bednarczyk; Carolina Medina-Montano; Frederic Julien Fittler; Henner Stege; Meike Roskamp; Michael Kuske; Christian Langer; Marco Vahldieck; Evelyn Montermann; Ingrid Tubbe; Nadine Röhrig; Andrzej Dzionek; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

6.  SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.

Authors:  Joshua M Carmen; Shikha Shrivastava; Zhongyan Lu; Alexander Anderson; Elaine B Morrison; Rajeshwer S Sankhala; Wei-Hung Chen; William C Chang; Jessica S Bolton; Gary R Matyas; Nelson L Michael; M Gordon Joyce; Kayvon Modjarrad; Jeffrey R Currier; Elke Bergmann-Leitner; Allison M W Malloy; Mangala Rao
Journal:  NPJ Vaccines       Date:  2021-12-13       Impact factor: 7.344

Review 7.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

8.  Dithranol as novel co-adjuvant for non-invasive dermal vaccination.

Authors:  Julian Sohl; Ann-Kathrin Hartmann; Jennifer Hahlbrock; Joschka Bartneck; Michael Stassen; Matthias Klein; Matthias Bros; Stephan Grabbe; Federico Marini; Kevin Woods; Borhane Guezguez; Matthias Mack; Hansjörg Schild; Sabine Muth; Felix Melchior; Hans Christian Probst; Peter Langguth; Markus P Radsak
Journal:  NPJ Vaccines       Date:  2022-09-24       Impact factor: 9.399

Review 9.  Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer.

Authors:  Enrica Marmonti; Jacqueline Oliva-Ramirez; Cara Haymaker
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 10.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.